Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up

Rita Ehrlich, Thomas A. Ciulla, Adam M. Moss, Alon Harris

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose: To report 6 months of results of combined treatment of intravitreal bevacizumab and triamcinolone in patients with retinal vein occlusion (RVO). Study design/Methods: Retrospective consecutive case series. Intravitreal bevacizumab (1.25 mg) combined with intravitreal triamcinolone (2 mg) was injected to 16 patients with RVO: eight with branch retinal vein occlusion (BRVO) and eight with central retinal vein occlusion (CRVO). Patient's charts were reviewed for age, sex, previous ocular interventions, duration of follow-up, number of intraocular injections, intraocular pressure (IOP) and central macular thickness measured by optical coherence tomography (OCT). We included only patients that completed 6 months of follow-up. Results: Mean age and number of injections were 72.9±11.99 years, and 2±0.81 respectively. In eight patients with CRVO, initial visual acuity was logMAR 1.09±0.67 and mean visual acuity at 1, 3 and 6 months was logMAR 0.98±0.55 (p=0.59), 1.33±1.05 (p=0.4) and 1.4±1.2 (p=0.34) respectively. In eight patients with BRVO, initial visual acuity was logMAR 1.025±0.58 and mean visual acuity at 1, 3, and 6 months was 0.56±0.21 (p=0.05), 0.61±0.17 (p=0.03) and 0.66±0.34 (p=0.12) respectively. Mean initial central macular thickness for the whole group was 527±182 μm and mean central macular thickness at 6 months was 379±156 μm (p<0.001). Conclusion: This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural outcome in patients with retinal vein occlusion. In our study, the combination of triamcinolone acetonide and bevacizumab offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision at 6 months

Original languageEnglish
Pages (from-to)375-380
Number of pages6
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume248
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Triamcinolone
Retinal Vein Occlusion
Visual Acuity
Retinal Vein
Therapeutics
Intraocular Injections
Triamcinolone Acetonide
Intravitreal Injections
Optical Coherence Tomography
Bevacizumab
Intraocular Pressure
Injections

Keywords

  • Bevacizumab
  • Triamcinolone
  • Vein occlusion

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion : 6 months of follow-up. / Ehrlich, Rita; Ciulla, Thomas A.; Moss, Adam M.; Harris, Alon.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 248, No. 3, 2010, p. 375-380.

Research output: Contribution to journalArticle

@article{7c05fe2141da4e14b074e7295567758d,
title = "Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up",
abstract = "Purpose: To report 6 months of results of combined treatment of intravitreal bevacizumab and triamcinolone in patients with retinal vein occlusion (RVO). Study design/Methods: Retrospective consecutive case series. Intravitreal bevacizumab (1.25 mg) combined with intravitreal triamcinolone (2 mg) was injected to 16 patients with RVO: eight with branch retinal vein occlusion (BRVO) and eight with central retinal vein occlusion (CRVO). Patient's charts were reviewed for age, sex, previous ocular interventions, duration of follow-up, number of intraocular injections, intraocular pressure (IOP) and central macular thickness measured by optical coherence tomography (OCT). We included only patients that completed 6 months of follow-up. Results: Mean age and number of injections were 72.9±11.99 years, and 2±0.81 respectively. In eight patients with CRVO, initial visual acuity was logMAR 1.09±0.67 and mean visual acuity at 1, 3 and 6 months was logMAR 0.98±0.55 (p=0.59), 1.33±1.05 (p=0.4) and 1.4±1.2 (p=0.34) respectively. In eight patients with BRVO, initial visual acuity was logMAR 1.025±0.58 and mean visual acuity at 1, 3, and 6 months was 0.56±0.21 (p=0.05), 0.61±0.17 (p=0.03) and 0.66±0.34 (p=0.12) respectively. Mean initial central macular thickness for the whole group was 527±182 μm and mean central macular thickness at 6 months was 379±156 μm (p<0.001). Conclusion: This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural outcome in patients with retinal vein occlusion. In our study, the combination of triamcinolone acetonide and bevacizumab offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision at 6 months",
keywords = "Bevacizumab, Triamcinolone, Vein occlusion",
author = "Rita Ehrlich and Ciulla, {Thomas A.} and Moss, {Adam M.} and Alon Harris",
year = "2010",
doi = "10.1007/s00417-009-1211-6",
language = "English",
volume = "248",
pages = "375--380",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion

T2 - 6 months of follow-up

AU - Ehrlich, Rita

AU - Ciulla, Thomas A.

AU - Moss, Adam M.

AU - Harris, Alon

PY - 2010

Y1 - 2010

N2 - Purpose: To report 6 months of results of combined treatment of intravitreal bevacizumab and triamcinolone in patients with retinal vein occlusion (RVO). Study design/Methods: Retrospective consecutive case series. Intravitreal bevacizumab (1.25 mg) combined with intravitreal triamcinolone (2 mg) was injected to 16 patients with RVO: eight with branch retinal vein occlusion (BRVO) and eight with central retinal vein occlusion (CRVO). Patient's charts were reviewed for age, sex, previous ocular interventions, duration of follow-up, number of intraocular injections, intraocular pressure (IOP) and central macular thickness measured by optical coherence tomography (OCT). We included only patients that completed 6 months of follow-up. Results: Mean age and number of injections were 72.9±11.99 years, and 2±0.81 respectively. In eight patients with CRVO, initial visual acuity was logMAR 1.09±0.67 and mean visual acuity at 1, 3 and 6 months was logMAR 0.98±0.55 (p=0.59), 1.33±1.05 (p=0.4) and 1.4±1.2 (p=0.34) respectively. In eight patients with BRVO, initial visual acuity was logMAR 1.025±0.58 and mean visual acuity at 1, 3, and 6 months was 0.56±0.21 (p=0.05), 0.61±0.17 (p=0.03) and 0.66±0.34 (p=0.12) respectively. Mean initial central macular thickness for the whole group was 527±182 μm and mean central macular thickness at 6 months was 379±156 μm (p<0.001). Conclusion: This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural outcome in patients with retinal vein occlusion. In our study, the combination of triamcinolone acetonide and bevacizumab offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision at 6 months

AB - Purpose: To report 6 months of results of combined treatment of intravitreal bevacizumab and triamcinolone in patients with retinal vein occlusion (RVO). Study design/Methods: Retrospective consecutive case series. Intravitreal bevacizumab (1.25 mg) combined with intravitreal triamcinolone (2 mg) was injected to 16 patients with RVO: eight with branch retinal vein occlusion (BRVO) and eight with central retinal vein occlusion (CRVO). Patient's charts were reviewed for age, sex, previous ocular interventions, duration of follow-up, number of intraocular injections, intraocular pressure (IOP) and central macular thickness measured by optical coherence tomography (OCT). We included only patients that completed 6 months of follow-up. Results: Mean age and number of injections were 72.9±11.99 years, and 2±0.81 respectively. In eight patients with CRVO, initial visual acuity was logMAR 1.09±0.67 and mean visual acuity at 1, 3 and 6 months was logMAR 0.98±0.55 (p=0.59), 1.33±1.05 (p=0.4) and 1.4±1.2 (p=0.34) respectively. In eight patients with BRVO, initial visual acuity was logMAR 1.025±0.58 and mean visual acuity at 1, 3, and 6 months was 0.56±0.21 (p=0.05), 0.61±0.17 (p=0.03) and 0.66±0.34 (p=0.12) respectively. Mean initial central macular thickness for the whole group was 527±182 μm and mean central macular thickness at 6 months was 379±156 μm (p<0.001). Conclusion: This study suggests that combined treatment with intravitreal bevacizumab and intravitreal triamcinolone improves structural outcome in patients with retinal vein occlusion. In our study, the combination of triamcinolone acetonide and bevacizumab offered no advantage over previously published results with intravitreal bevacizumab injections alone for improving vision at 6 months

KW - Bevacizumab

KW - Triamcinolone

KW - Vein occlusion

UR - http://www.scopus.com/inward/record.url?scp=77949268295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949268295&partnerID=8YFLogxK

U2 - 10.1007/s00417-009-1211-6

DO - 10.1007/s00417-009-1211-6

M3 - Article

C2 - 19898827

AN - SCOPUS:77949268295

VL - 248

SP - 375

EP - 380

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 3

ER -